This research retrospectively studied mobilization efficacy and safety using etoposide combined with Cytarabine (etoposide 50–100 mg/m2, qd d1–3; AraC 0.5 g/m2, q12h d1~3) plus G-CSF (5 μg/kg/day, from d5 until the day of apheresis) in 128 patients with MM. The gene discussed is CSF3; the disease is Miyoshi myopathy.